Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

28.6%

2 terminated/withdrawn out of 7 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 2 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 2

5(71.4%)

Phase 1

1(14.3%)

N/A

1(14.3%)

7Total

Phase 2(5)

Phase 1(1)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT06880198Not ApplicableRecruiting

Study to Evaluate Impact® as Support to Anti PD1 or Anti PD1 Based Regimen Treatment in Patients With Inoperable Locally Advanced or Metastatic Melanoma

Role: lead

NCT04632433Phase 2Active Not Recruiting

Neoadjuvant Plus Adjuvant Treatment With Cemiplimab in Cutaneaous Squamous Cell Carcinoma

Role: lead

NCT04722575Phase 2Active Not Recruiting

Combination or Sequence of Vemurafenib, Cobimetinib, and Atezolizumab in High-risk, Resectable Melanoma

Role: lead

NCT02631447Phase 2Completed

Sequential Combo Immuno and Target Therapy (SECOMBIT) Study

Role: lead

NCT05299580Phase 2Withdrawn

"Dabrafenib and Trametinib in Circulating Free DNA BRAFV600 Mutated Metastatic Melanoma Patients: a Prospective Phase II, Open Label, Multicentre Study - (Bioliquid TAILOR Study - BIOTAILOR)"

Role: lead

NCT01959633Phase 1Completed

Vemurafenib Plus Cobimetinib Plus PEG-interferon in Advanced Melanoma Patients Harboring the V600BRAF Mutation

Role: lead

NCT03224208Phase 2Terminated

Vemurafenib Plus Cobimetinib in Advanced or Metastatic Melanoma Patients

Role: lead

All 7 trials loaded